Amgen is a well-known biotechnology company that focuses on creating medicines to treat serious health conditions like cancer, bone diseases, and heart problems. Its stock is popular among investors who believe in the power of science and innovation. Amgen has a strong track record of producing important drugs, and it continues to invest in research to discover new treatments. The company is also growing its reach through biosimilars, which are affordable versions of existing biologic medicines.
Current Market Overview of Amgen Stock
- Current Price:- 277.29
- Open:- 277.04
- High:- 278.68
- Low:- 268.50
- Mkt cap:- 14.91KCr
- P/E ratio:- 36.68
- Div yield:- 3.43%
- 52-wk high:- 346.85
- 52-wk low:- 253.30
Amgen Stock Price Chart
Amgen Stock Price Prediction Tomorrow From 2025 To 2030
| Amgen Stock Price Prediction Years | Amgen Stock Price |
| 2025 | $ 350 |
| 2026 | $ 400 |
| 2027 | $ 450 |
| 2028 | $ 500 |
| 2029 | $ 550 |
| 2030 | $ 600 |
Amgen Financials Statement
| ($) | 2024 | Y/Y change |
| Revenue | 33.42B | 18.57% |
| Operating expense | 13.29B | 23.78% |
| Net income | 4.09B | -39.11% |
| Net profit margin | 12.24 | 6.38% |
| Earnings per share | 19.84 | 77.26% |
| EBITDA | 15.16B | 11.53% |
| Effective tax rate | 11.26% | — |
Amgen Stock Price Prediction 2025
Here are 8 Key Factors Affecting Growth for Amgen Stock Price Prediction in 2025:
-
Strong Product Portfolio
Amgen’s well-established drugs, like Enbrel, Prolia, and Repatha, continue to contribute significantly to its revenue, supporting stable growth. -
Development of New Drugs
A successful pipeline of new therapies, especially in areas like oncology, inflammation, and biosimilars, can boost future earnings. -
Biosimilar Expansion
Amgen is a leader in biosimilars (cheaper versions of biologic drugs). Continued growth in this area can help the company reach more markets and customers. -
Strategic Acquisitions
Acquiring smaller biotech firms with promising products or technologies can strengthen Amgen’s portfolio and future revenue potential. -
Aging Global Population
As the population ages, demand for treatments related to bone health, cancer, and chronic diseases is expected to rise, benefiting Amgen’s core offerings. -
Global Market Penetration
Expanding into emerging markets with high healthcare needs could provide new revenue streams and increase global brand presence. -
Research and Development Investment
Consistent R&D spending allows Amgen to innovate and stay competitive by discovering new, effective treatments. -
Favorable Regulatory Approvals
Faster or favorable FDA and global approvals for pipeline drugs could speed up time-to-market and enhance revenue growth in the short term.
Amgen Stock Price Prediction 2030
Here are 8 Risks and Challenges for Amgen Stock Price Prediction in 2030:
-
Patent Expirations
Loss of exclusivity on major drugs like Enbrel and Prolia by 2030 could lead to increased generic and biosimilar competition, reducing revenue. -
Regulatory Delays or Rejections
If Amgen faces delays or denials from the FDA or other health authorities for its new drugs, it could slow growth and impact investor confidence. -
R&D Failures
Developing new drugs is expensive and uncertain. Failed clinical trials or ineffective treatments can lead to major financial losses. -
Pricing Pressures
Governments and insurers around the world are pushing for lower drug prices, which can hurt Amgen’s profit margins, especially in the U.S. -
Litigation Risks
Like many pharmaceutical companies, Amgen may face lawsuits over drug safety or patent issues, leading to legal expenses and reputational harm. -
Biosimilar Competition
While Amgen develops biosimilars, it also faces strong competition from other companies producing biosimilar versions of its own drugs. -
Global Economic Uncertainty
Economic slowdowns or unstable currency exchange rates in key international markets may impact sales and overall financial performance. -
Technological Disruption
Rapid advances in biotechnology or newer treatment methods from competitors could make some of Amgen’s therapies less relevant or obsolete.
Read Also:- Goldman Sachs Stock Price Prediction Tomorrow From 2025 To 2030
